Skip to main content

Published locations for Risankizumab in Crohn’s Disease: Clinical, Endoscopic Outcomes Remain Stable for up to 3 Years

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Risankizumab in Crohn’s Disease: Clinical, Endoscopic Outcomes Remain Stable for up to 3 Years

User login

  • Reset your password
  • /content/risankizumab-crohns-disease-clinical-endoscopic-outcomes-remain-stable-3-years
  • /familypracticenews/article/268026/ibd-intestinal-disorders/risankizumab-crohns-disease-clinical
  • /gihepnews/article/268026/ibd-intestinal-disorders/risankizumab-crohns-disease-clinical-endoscopic
  • /internalmedicinenews/article/268026/ibd-intestinal-disorders/risankizumab-crohns-disease-clinical
  • /internalmedicine/article/268026/ibd-intestinal-disorders/risankizumab-crohns-disease-clinical
  • /familymedicine/article/268026/ibd-intestinal-disorders/risankizumab-crohns-disease-clinical